Skip to main content
  1. Right Decisions
  2. DGRefHelp - NHS Dumfries & Galloway
  3. Sexual health
  4. Back
  5. Infections - not STIs
  6. Bacterial Vaginosis
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Bacterial Vaginosis

Warning

What’s New

Tinidazole no longer available
Delaquinium chloride is a licensed 2nd line option
Note IUSTI guideline advice that BV commoner in women with an IUCD

 

Bacterial Vaginosis is the most common microbiological cause of abnormal vaginal discharge.
It is caused by an overgrowth of anaerobic organisms.

  • Thin, offensive smelling vaginal discharge
  • Vaginal odour

Frequently recurs


NB: Not typically associated with itch, soreness or irritation

Thin, white homogenous discharge coating introitus and vaginal walls, it may look slightly frothy. A characteristic odour is often noted
NB: vulval inflammation is not typical in BV

In genitourinary settings two approaches to the diagnosis of BV are widely used:

Amsel’s criteria and the Hay/Ison criteria 1. Both require microscopy to be available, which is not always the case in sexual health clinics. Where available, microscopy can be used, but syndromic management is supported by national guidelines1,2

The Hay/Ison Criteria (used in the NaSH microscopy page) are:
Grade 0 no bacteria seen
Grade 1 (Normal): Lactobacillus morphotypes predominate
Grade 2 (Intermediate): Mixed flora with some Lactobacilli present, but Gardnerella or Mobiluncus morphotypes also present
Grade 3 (BV): Predominantly Gardnerella and/or Mobiluncus morphotypes. Few or absent Lactobacilli.
Grade 4 Gram positive cocci predominate (consider aerobic vaginitis)

Amsel’s criteria are at least three out of:
(1) Thin, white, homogeneous discharge
(2) Clue cells on microscopy of wet mount
(3) pH of vaginal fluid >4.5
(4) Release of a fishy odour on adding alkali (10% KOH).

History
Diagnosis can be made on the basis of

  • history of offensive, non-itchy discharge
  • absence of pelvic/vulval pain and abnormal bleeding
  • Patient is not pregnant, post-partum or post-gynaecological instrumentation
  • Vaginal pH >4.5

It is important to take a sexual history to consider the risk of STI and offer STI testing as appropriate as Chlamydia and Gonorrhoea can co-exist. A cervical screening history should be taken as cervical cancer is a differential diagnosis of a smelly discharge. Also consider if a tampon could have been retained.

If possible undertake vulval and speculum examination to visualise any discharge. Inspect the cervix to
exclude any abnormality as a cause of offensive discharge.

Tests options

  • Vaginal pH: collect a specimen of the discharge from the vaginal walls with a loop or swab and
    apply to narrow gauge pH 4-7 testing strip paper. e.g. from Whatman www.whatman.com  Normal vaginal pH is <4.5 and a pH above this is seen in BV. NB: Semen, blood and some lubricants are also alkaline.
  • Alternatively VISION ph sticks can be used these are available from www.sutherlandhealth.com
  • If available – Microscopy
    • Wet mount to look for clue cells
    • Gram stained slide from vaginal wall. BV suggested if: absent or reduced lactobacilli;
      predominance of gardnerella/mobiluncus morphotypes
      (Hay/Ison grade 3)1
      N.B. Slides can be air dried and sent to the lab for staining and microscopy. Check local arrangements

Not recommended:

High vaginal swabs are of limited value in diagnosing BV as organisms such as gardnerella can be present in 30-40% asymptomatic women. A culture reported as normal does not exclude clinical BV. Microscopy and vaginal pH are far more useful and women reporting recurrent symptoms are better to have a microscopy slide taken.

Asymptomatic women do not need treatment (asymptomatic women should not be being diagnosed as
without symptoms there is no indication to take a test).

General advice
The best ways of preventing BV are not know but avoiding anything that upsets the natural balance of
bacteria in the vagina may help. This includes avoiding:

  • Douching
  • Frequent washing or bathing
  • Bubble baths, scented soaps, antiseptics such as Dettol and feminine washes

Use of emollients as a soap substitute for the genital area (available from any pharmacy) is recommended.
BV is more common in women with an IUCD5
If a woman is experiencing recurrent episodes of BV alternative methods can be discussed.

1st line

 

Metronidazole 400mg oral twice daily 5-7 days (slightly lower relapse rate)
1st line in pregnancy
OR
Metronidazole 2g single oral dose (not recommended in pregnancy)

 

  • Other 1st line options intravaginal metronidazole gel (0.75%) per vagina once daily for 5 days OR
    intravaginal clindamycin 2% cream per vagina once daily for 7 days (nb these vaginal preparations
    weaken condoms, clindamycin also has a risk of pseudomembranous colitis) These are significantly
    more expensive than oral metronidazole
  • Advise patients to avoid alcohol during and for 48 hours after any metronidazole treatment due to the
    combination being likely to cause nausea and vomiting, tachycardia, hot flushes and palpitations

 

2nd Line 

 

Clindamycin 300mg oral twice daily 7 days (risk of pseudomembranous colitis)
Or
Dequalinium chloride 10mg vaginal tablets One 10mg vaginal tablet daily for six days6

 

Insufficient evidence to assess effectiveness but anecdotally useful

Licensed indications

Treatment of BV in adults

Relactagel® : 5 mL( 1 tube) to vagina nightly for 7 nights
Relactagel® is unsuitable for people with an allergy to shellfish as the glycogen is derived from oysters.
There may be a potential risk to a partner who is allergic to shellfish if these have been used.
Balance Activ® is not licenced for treatment

Refer to WOS Pregnancy and STI’s Guideline instead

Non–pregnant women: Not necessary unless symptomatic
Pregnant women: test of cure after a month1

No evidence of benefit in studies of screening and treating male partners
No studies of treatment in female partners although high incidence in female partners of women with BV. If a
female partner is asymptomatic treatment need not be offered routinely.

Consider alternative diagnosis
Check compliance with treatment
Try alternative therapy option - longer course of metronidazole may be more effective than single dose

Sporadic Recurrences
Up to 30% of women have a recurrence within 3 months
Examination and investigation should be considered but may not be necessary if a previous episode of the
signs and symptoms of BV responded to antibiotic treatment, and there are no grounds to suspect an STI or
cervical abnormality.

Frequent Recurrences of Bacterial Vaginosis
This is widely defined as more than four recurrences per year.
Speculum examination should be carried out. The diagnosis should be confirmed with microscopy or HVS.
Negative swabs (or negative dry slide) and persistent symptoms should prompt referral to a sexual health
clinic with microscopy available.
Persistent, symptomatic BV may be associated with the presence of an IUD and an alternative method of
contraception may need to be considered if there is no response to therapy.

Suppressive/preventive treatment

 400mg metronidazole oral twice daily for 3 days at start and/or end of menstruation

or

5g 0.75% metronidazole gel intravaginally twice weekly for 16 weeks     

or   

Relactagel®: 5 mL (1 tube) nightly to vagina for 2–3 nights after menstruation

or 

Balance Activ RX gel® 5 mL (1 tube) to vagina 1–2 times a week

 

  1. Clinical effectiveness Group BASHH. UK guideline for the management of Bacterial Vaginosis 2012
    https://www.bashhguidelines.org/media/1041/bv-2012.pdf accessed 14/05/2021
  2. RCGP Sex drugs and Viral Hepatitis group, British Association for Sexual Health and HIV. Sexually
    transmitted infections in primary care . Second Edition 2013 https://www.bashh.org/documenhttps://www.bashhguidelines.org/media/1041/bv2012.pdfts/Sexually%20Transmitted%20Infections%20in%20Primary%20Care%202013.pdf accessed 14/05/2023
  3. NHS Clinical Knowledge Summaries, Bacterial Vaginosis last revised 2018
    Bacterial vaginosis | Health topics A to Z | CKS | NICE accessed 14/05/2021
  4. https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalini
    um_Fluomizin
  5. Sherrard, J., Wilson, J. and Donders G. et al. (2018) 2018 European (IUSTI/WHO) guideline on the
    management of vaginal discharge. http://www.iusti.org accessed 14/05/2021

British National Formulary prices accessed February 2021 NB local contracts may result in
different prices.

Metronidazole 2g  £1.07*
Metronidazole 400mg b.d. 7 days £3.50-4.50
Metronidazole gel  £4.31
Clindamycin 2% Cream  £10.86
Clindamycin 300mg b.d. 7 days £17.84
Relactagel 7 x 5ml tubes  £5.25
Balance Activ 7 x 5ml tubes  £5.25
Delquinium Chloride( Fluomizin)  £6.95

Not in BNF : local over labelled pack price 2020
 

Patient information leaflets 

 

BV information leaflet
https://www.bashhguidelines.org/media/1124/bv_pil_print_2014.pdf (accessed 14/05/2021)

What do you know about...Vaginal health?
http://www.healthscotland.com/documents/3419.aspx

online versions in English, Polish, Chinese, Urdu, Romanian (accessed 14/05/2021)

Editorial Information

Last reviewed: 31/05/2021

Next review date: 31/05/2025

Author(s): West of Scotland Managed Clinical Network in Sexual Health Clinical Guidelines Group .

Version: 5.1

Author email(s): janice.allan@nhs.scot .

Approved By: West of Scotland Managed Clinical Network in Sexual Health